{"id":781959,"date":"2023-09-06T06:58:34","date_gmt":"2023-09-06T10:58:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/"},"modified":"2023-09-06T06:58:34","modified_gmt":"2023-09-06T10:58:34","slug":"pharvaris-to-present-at-the-18th-german-allergy-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/","title":{"rendered":"Pharvaris To Present at the 18th German Allergy Congress"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland, Sept.  06, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J4ma16zULuDpOFMSdcpBE6ckHIRsQ-WAA129Y_3Ch2TsZDfrXVKAcwIo2KdDwAj9mqpTATmos3Po29xBm9lwdA==\" rel=\"nofollow noopener\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023.<\/p>\n<p>\n        <strong>Presentation details:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title: <\/strong>Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial<br \/><strong>Presenter:<\/strong> Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.<br \/><strong>Date, Time: <\/strong>Friday, September 15, 5:15-6:30 p.m. CEST<br \/><strong>Poster ID: <\/strong>A-194<\/p>\n<\/li>\n<li>\n          <strong>Title: <\/strong>Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks<br \/><strong>Presenter: <\/strong>Markus Magerl, M.D.<br \/><strong>Date, Time: <\/strong>Friday, September 15, 5:15-6:30 p.m. CEST<br \/><strong>Poster ID: <\/strong>A-264<\/li>\n<\/ul>\n<p>The abstracts will be published in the congress issue of the <em>Allergo Journal International<\/em> and <em>Allergologie.<\/em> After the close of the ePoster session \u201cAngioedema,\u201d the posters will be made available on the Investors section of the Pharvaris website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=10fCQqnJBb_Up4EuKGAbD2xpeMqQ8kcMDmIWzhGNTMS8xa1ZDLEwv6D11GjbcUX-p8rFK3CXXOPCkCyKSVy78uC4zaiVmPpLRKqeazrK1oKMGG4e3ahjmeHby-qiCSfuX-Whr1qleLksSzZYwnGa6HHoDbIFI6biGiUZSDbSAkoEkMhIDjZ8x4CAGqo_meFkFN2TSEGh8-oSzsC78t2worEOcFARQkSIztJ5pKwOWN8ngOOJnlYhIGTbFSmQvGSUkVsN3yv0SOfWP3IwANopBRrzPEdSZNP293MfptIqOcayPYUiX1ynO7shgqbYHAivm13i21yskc3Yp6HTiasKVz6902NcVmQ6PiMiTa6MIBE210_lIJ-YB922pVmAhnVlZ8RrzJnrbOzP8jwXwdYkgn9InX2oXsMQ04WUapvdVbA=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About Pharvaris<\/strong><br \/>\n        <br \/>Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=10fCQqnJBb_Up4EuKGAbDwU5csBMMSroejHZz-3jV2VLlS7d8whuLissIrAMY33fSmBBLHTh0YgHlu1r-hWlpqYOLjnol7WluUlidnrtYTgPZQtZ6o-_MWrMBXhsOshMYAkE4FL5tU925XwQEFiOQvri0JLG4WTs5GoalzU1HxRUm9PgE-ZmPmFkHl_NAuvm6S2R0pXtmxT38IO_wBN65nZAl1Qn40aoMji8M5SWFNiZIgJgc7Hhm77JVP5rjauEW5AmiOq7WV3PB_1WnaLGDg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/pharvaris.com\/<\/a>.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWE3MTIwYWEtNjEwOS00MjA5LTljZjAtZWQyODE2YzY2NzVjLTEyMTc1MDA=\/tiny\/Pharvaris-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact\r\nMaggie Beller\r\nExecutive Director, Head of External and Internal Communications\r\nMaggie.beller@pharvaris.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023. Presentation details: Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trialPresenter: Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.Date, Time: Friday, September 15, 5:15-6:30 p.m. CESTPoster ID: A-194 Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacksPresenter: Markus Magerl, M.D.Date, Time: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris To Present at the 18th German Allergy Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781959","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023. Presentation details: Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trialPresenter: Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.Date, Time: Friday, September 15, 5:15-6:30 p.m. CESTPoster ID: A-194 Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacksPresenter: Markus Magerl, M.D.Date, Time: &hellip; Continue reading &quot;Pharvaris To Present at the 18th German Allergy Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-06T10:58:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris To Present at the 18th German Allergy Congress\",\"datePublished\":\"2023-09-06T10:58:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/\",\"name\":\"Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\",\"datePublished\":\"2023-09-06T10:58:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-at-the-18th-german-allergy-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris To Present at the 18th German Allergy Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk","og_description":"ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023. Presentation details: Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trialPresenter: Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.Date, Time: Friday, September 15, 5:15-6:30 p.m. CESTPoster ID: A-194 Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacksPresenter: Markus Magerl, M.D.Date, Time: &hellip; Continue reading \"Pharvaris To Present at the 18th German Allergy Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-06T10:58:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris To Present at the 18th German Allergy Congress","datePublished":"2023-09-06T10:58:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/","name":"Pharvaris To Present at the 18th German Allergy Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=","datePublished":"2023-09-06T10:58:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE4NCM1ODAwMjIwIzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-at-the-18th-german-allergy-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris To Present at the 18th German Allergy Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781959"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781959\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}